A novel antisense oligonucleotide inhibiting several antiapoptotic Bcl-2 family members induces apoptosis and enhances chemosensitivity in androgen-independent human prostate cancer PC3 cells

Molecular Cancer Therapeutics

Volumn 4, Issue 11, 2005, Pages 1689-1698

  Yamanaka, Kazuki ^a   Rocchi, Palma ^a   Miyake, Hideaki ^c   Fazli, Ladan ^a   Vessella, Bob ^d   Zangemeister Wittke, Uwe ^e   Gleave, Martin E ^a,b  

^a VANCOUVER GENERAL HOSPITAL   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c HYOGO MEDICAL CENTER FOR ADULTS   (Japan)

^d UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANTISENSE OLIGONUCLEOTIDE; CASPASE 3; CASPASE 6; CASPASE 7; INHIBITOR OF APOPTOSIS PROTEIN; ISIS 279228; MESSENGER RNA; PACLITAXEL; PROTEIN BAD; PROTEIN BAK; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN MCL 1; UNCLASSIFIED DRUG; X LINKED INHIBITOR OF APOPTOSIS;

AMINO ACID SEQUENCE; APOPTOSIS; ARTICLE; CANCER CELL; CHEMOSENSITIVITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; DRUG TARGETING; GENE TARGETING; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CANCER; PROTEIN FUNCTION; SEQUENCE ANALYSIS; SEQUENCE HOMOLOGY;

EID: 28044468839     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-05-0064     Document Type: Article

References (46)

1. Denis L, Murphy GP. Overview of phase III trials on combined androgen treatment in patients with metastatic cancer. Cancer (Phila) 1993;72: 3888-95.
2. Tannock IF, De Wit R, Berry WR, et al. for the TAX 327 Investigators. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351:1502-12.
3. Petrylak DP, Tangen CM, Hussian MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004;351:1513-20.
4. Gleave ME, Zellweger T, Chi K, et al. Targeting anti-apoptotic genes upregulated by androgen withdrawal using antisense oligodeoxynucleotides to enhance androgen- and chemo-sensitivity in prostate cancer. Invest New Drugs 2002;20:145-58.
5. Nunez G, Clarke MF. The bcl-2 family of proteins: regulators of cell death and survival. Trends Cell Biol 1994;4:399-403.
6. Chao DT, Korsmeyer SJ. Bcl-2 family: regulators of cell death. Annu Rev Immunol 1998;16:395-419.
7. Tsujimoto Y, Croce CM. Analysis of the structure, transcripts, and protein products of bcl-2, the gene involved in human follicular lymphoma. Proc Natl Acad Sci U S A 1986;83:5214-8.
8. Boise LH, Gonzalez-Garcia M, Postema CE, et al. Bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death. Cell 1993;74:597-608.
9. McDonnell TJ, Troncoso P, Brisbay SM, et al. Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res 1992;52:6940-4.
10. Colombel M, Symmans F, Gil S, et al. Detection of the apoptosis-suppressing oncoprotein bc1-2 in hormone-refractory human prostate cancers. Am J Pathol 1993;143:390-400.
11. McConkey DJ, Greene G, Pettaway CA. Apoptosis resistance increases with metastatic potential in cells of the human LNCaP prostate carcinoma line. Cancer Res 1996;56:5594-9.
12. Miyake H, Monia B, Gleave ME. Antisense Bcl-xL and Bcl-2 Oligodeoxynucleotides synergistically enhance Taxol chemosensitivity and delay progression to androgen-independence after castration in the androgen dependent Shionogi tumor model. Int J Cancer 2000;86:855-62.
13. Lebedeva I, Rando R, Ojwang J, Cossum P, Stein CA. Bcl-xL in prostate cancer cells: effect of overexpression and down-regulation on chemotherapy. Cancer Res 2000;60:6052-60.
14. Han Z, Chatterjee D, Early J, Pantazis P, Hendrickson EA, Wyche JH. Isolation and characterization of an apoptosis-resistant variant of human leukemia HL-60 cells that has switches expression from Bcl-2 to Bcl-xL. Cancer Res 1996;56:1621-8.
15. Gewirtz AM, Sokol DL, Ratajczak MZ. Nucleic acid therapeutics: state of the art and future prospects. Blood 1998;92:712-36.
16. Monia BP, Johnston JF, Geiger T, Muller M, Fabbro D. Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against C-raf kinase. Nat Med 1996;2:668-75.
17. Ziegler A, Luedke GH, Fabbro D, Altmann KH, Stahel RA, Zangemeister-Wittke U. Induction of apoptosis in small-cell lung cancer cells by an antisense oligodeoxynucleotide targeting the Bcl-2 coding sequence. J Natl Cancer Inst 1997;89:1027-36.
18. Zangemeister-Wittke U, Schenker T, Luedke GH, Stahel RA. Synergistic cytotoxicity of bcl-2 antisense oligodeoxynucleotides and etoposide, doxorubicin and cisplatin on small-cell lung cancer cell lines. Br J Cancer 1998;78:1035-42.
19. Miyake H, Nelson C, Rennie PS, Gleave ME. Acquisition of chemoresistant phenotype by overexpression of the antiapoptotic gene testosterone-repressed prostate message-2 in prostate cancer xenograft models. Cancer Res 2000;60:2547-54.
20. Jansen B, Schlagbauer-Wadle H, Brown BD, et al. Bcl-2 antisense therapy chemosensitizes human melanoma in SCID mice. Nat Med 1998; 4:232-4.
21. Miyake H, Tolcher A, Gleave ME. Chemosensitization and delayed androgen-independent recurrence of prostate cancer with the use of antisense Bcl-2 oligodeoxynucleotides. J Natl Cancer Invest 2000;92:34-41.
22. Zangemeister-Wittke U, Leech SH, Olie RA, et al. A novel bispecific antisense oligonucleotide inhibiting both Bcl-2 and Bcl-xL expression efficiently induces apoptosis in tumor cells. Clin Cancer Res 2000;6: 2547-55.
23. Gautschi O, Tschopp S, Olie RA, et al. Activity of a novel bcl-2/bcl-xL-bispecific antisense oligonucleotide against tumors of diverse histologic organs. J Natl Cancer Inst 2000;93:463-71.
24. Simoes-Wust AP, Schurpf T, Hall J, Stahel RA, Zangemeister-Wittke U. Bcl-2/bcl-xL bispecific antisense treatment sensitizes breast carcinoma cells to doxorubicin, paclitaxel and cyclophosphamide. Breast Cancer Res Treat 2002;76:157-66.
25. Olie RA, Hafner C, Kuttel R, et al. Bcl-2 and bcl-xL antisense oligonucleotides induce apoptosis in melanoma cells of different clinical stages. J Invest Dermatol 2002;118:506-12.
26. Jiang Z, Zheng X, Rich KM. Down-regulation of Bcl-2 and Bcl-xL expression with bispecific antisense treatment in glioblastoma cell lines induce cell death. J Neurochem 2003;84:273-81.
27. Simoes-Wust AP, Olie RA, Gautschi O, et al. Bcl-xL antisense treatment induces apoptosis in breast carcinoma cells. Int J Cancer 2000; 87:582-90.
28. Gibson UE, Heid CA, Williams PM. A novel method for real time quantitative RT-PCR. Genome Res 1996;6:995-1001.
29. Miyake H, Hanada N, Nakamura H, et al. Overexpression of Bcl-2 in bladder cancer cells inhibits apoptosis induced by cisplatin and adenoviral-mediated p53 gene transfer. Oncogene 1998;16:933-43.
30. Miyake H, Nelson C, Rennie PS, Gleave ME. Overexpression of insulin-like growth factor binding protein-5 helps accelerate progression to androgen-independence in the human prostate LNCaP tumor model through activation of phosphatidylinositol 3′-kinase pathway. Endocrinology 2000;141:2257-65.
31. Sun X, Bratton SB, Butterworth M, MacFarlane M, Cohen GM. Bcl-2 and Bcl-xL inhibit CD95-mediated apoptosis by preventing mitochondrial release of Smac/DIABLO and subsequent inactivation of X-linked inhibitor-of-apoptosis protein. J Biol Chem 2002;277:11345-51.
32. Rchaud S, Korfali N, Villa P, et al. Caspase-6 gene disruption reveals a requirement for lamine A cleavage in apoptotic chromatin condensation. EMBO J 2002;21:1967-77.
33. Simonian PL, Grillot DA, Nunez G. Bcl-2 and Bcl-xL can differentially block chemotherapy-induced cell death. Blood 1997;90:1208-16.
34. Gottschalk AR, Boise LH, Thompson CB, Quintans J. Identification of immunosuppressant-induced apoptosis in a murine B-cell line and its prevention by bcl-x but not bcl-2. Proc Natl Acad Sci U S A 1994;91:7350-4.
35. Arriola EL, Rodriguez-Lopez AM, Hickman JA, Chresta CM. Bcl-2 overexpression results in reciprocal downregulation of Bcl-X(L) and sensitizes human testicular germ cell tumours to chemotherapy-induced apoptosis. Oncogene 1999;18:1457-64.
36. Wunsche W, Tenniswood MP, Schneider MR, Vollmer G. Estrogenic regulation of clusterin mRNA in normal and malignant endometrial tissue. Int J Cancer 1998;76:684-8.
37. Bruchovsky N, Snoek R, Rennie P, Akakura K, Goldenberg SL, Gleave ME. Control of tumor progression by maintenance of apoptosis. Prostate 1996;6:13-21.
38. Gleave M, Tolcher A, Miyake H, et al. Progression to androgen independence is delayed by adjuvant treatment with antisense Bcl-2 oligodeoxynucleotides after castration in the LNCaP prostate tumor model. Clin Cancer Res 1999;5:2891-8.
39. Chi KN, Gleave ME, Klasa R, et al. A phase I dose-finding study of combined treatment with an antisense Bcl-2 oligonucleotide (Genesense) and mitoxantrone in patients with metastatic hormone-refractory prostate cancer. Clin Cancer Res 2001;7:3920-7.
40. Tolcher AW, Chi K, Kuhn J, et al. A phase II, pharmacokinetic, and biological correlative study of oblimersen sodium and docetaxel in patients with hormone-refractory prostate cancer. Clin Cancer Res 2005;11: 3854-61.
41. Gleave M, Monia BP. Antisense therapy for cancer. Nat Rev Cancer 2005;5:468-79.
42. Akgul C, Turner PC, White MR, Edwards SW. Functional analysis of the human MCL-1 gene. Cell Mol Life Sci 2000;57:684-91.
43. Bae J, Leo CP, Hsueh SY, Hsueh AJ. Mcl-1S, a splicing variant of the antiapoptotic Bcl-2 family member Mcl-1, encodes a proapoptotic protein possessing only the BH3 domain. J Biol Chem 2000;275:25255-61.
44. Yang T, Kozopas KM, Craig RW. The intracellular distribution and pattern of expression of Mcl-1 overlap with, but are not identical to, those of Bcl-2. J Cell Biol 1995;128:1173-84.
45. Krajewski M, Krajewski S, Epstein JI, et al. Immunohistochemical analysis of bcl-2, bax, bcl-X, and mcl-1 expression in prostate cancers. Am J Pathol 1996;148:1567-76.
46. Krajewska M, Krajewska S, Banares S, et al. Elevated expression of inhibitor of apoptosis proteins in prostate cancer. Clin Cancer Res 2003; 9:4914-25.